Cargando…

Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma

Despite extensive genetic diversity of HIV-1 in chronic infection, a single or few maternal virus variants become the founders of an infant’s infection. These transmitted/founder (T/F) variants are of particular interest, as a maternal or infant HIV vaccine should raise envelope (Env) specific IgG r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Amit, Smith, Claire E. P., Giorgi, Elena E., Eudailey, Joshua, Martinez, David R., Yusim, Karina, Douglas, Ayooluwa O., Stamper, Lisa, McGuire, Erin, LaBranche, Celia C., Montefiori, David C., Fouda, Genevieve G., Gao, Feng, Permar, Sallie R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908066/ https://www.ncbi.nlm.nih.gov/pubmed/29672607 http://dx.doi.org/10.1371/journal.ppat.1006944

Ejemplares similares

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
por: Martinez, David R., et al.
Publicado: (2020)

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site
por: McCurley, Nathanael P., et al.
Publicado: (2017)

Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys.
por: Himes, Jonathon E., et al.
Publicado: (2018)

The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells
por: Jeffries, Thomas L, et al.
Publicado: (2015)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers
por: Kumar, Amit, et al.
Publicado: (2021)

The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids
por: Mansour, Robin G, et al.
Publicado: (2016)

Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials
por: Hompe, Eliza D., et al.
Publicado: (2020)

The Role of Maternal HIV Envelope-Specific Antibodies and Mother-to-Child Transmission Risk
por: Douglas, Ayooluwa O., et al.
Publicado: (2017)

Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models
por: Pollara, Justin, et al.
Publicado: (2019)

Determinants of Tenascin-C and HIV-1 envelope binding and neutralization
por: Mangan, Riley J., et al.
Publicado: (2019)

Noncanonical placental Fc receptors: What is their role in modulating transplacental transfer of maternal IgG?
por: Martinez, David R., et al.
Publicado: (2018)

Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus
por: Manoharan, Vinoth K., et al.
Publicado: (2018)

Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1
por: Tay, Matthew Zirui, et al.
Publicado: (2019)

Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome
por: Song, Hongshuo, et al.
Publicado: (2012)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques
por: Pahar, Bapi, et al.
Publicado: (2016)

Transmitted/Founder Simian Immunodeficiency Virus Envelope Sequences in Vesicular Stomatitis and Semliki Forest Virus Vector Immunized Rhesus Macaques
por: Gambhira, Ratish, et al.
Publicado: (2014)

Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
por: Parrish, Nicholas F., et al.
Publicado: (2012)

Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
por: Foster, Toshana L., et al.
Publicado: (2016)

Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques
por: Rosenberg, Yvonne J., et al.
Publicado: (2016)

Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine
por: Cai, Hui, et al.
Publicado: (2018)

Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences
por: Song, Hongshuo, et al.
Publicado: (2016)

Systemic administration of an HIV 1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization
por: Fouda, Genevieve G., et al.
Publicado: (2016)

Understanding Early-Life Adaptive Immunity to Guide Interventions for Pediatric Health
por: Semmes, Eleanor C., et al.
Publicado: (2021)

Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants
por: Fouda, Genevieve G, et al.
Publicado: (2013)

Sexually-Transmitted/Founder HIV-1 Cannot Be Directly Predicted from Plasma or PBMC-Derived Viral Quasispecies in the Transmitting Partner
por: Frange, Pierre, et al.
Publicado: (2013)

CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses
por: Lewis, Phoebe E., et al.
Publicado: (2020)

Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study
por: Hompe, Eliza D., et al.
Publicado: (2019)

Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop
por: Qin, Yali, et al.
Publicado: (2015)

Identification of early-induced broadly neutralizing activities against transmitted founder HIV strains
por: Lucas, Julie, et al.
Publicado: (2023)

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
por: Goonetilleke, Nilu, et al.
Publicado: (2009)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat
por: Montefiori, David C., et al.
Publicado: (2021)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
por: Parks, K. Rachael, et al.
Publicado: (2019)

Sexually transmitted founder HIV-1 viruses are relatively resistant to Langerhans cell-mediated restriction
por: Hertoghs, Nina, et al.
Publicado: (2019)

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer
por: Ananthaswamy, Neeti, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3s74e9obr8kgi431n11ni640bd